Un anticuerpo optimizado con especificidad para CD19/CD22/CD3 ha mostrado potencial para la inmunoterapia oncológica, en un modelo murino de leucemia linfoblástica aguda de células B. Puede leer un comentario al respecto en Müller D. Optimized CD19/CD22/CD3 antibody. Blood, 2022;140(16):1750–1751.
– Vázquez-Blomquist D, Bequet-Romero M, Mendoza-Marí Y, Lemos G, Valdés I, Canaán-Haden C, et al. Nasalferon, a new nasal formulation of IFNa2b, modulates cellular and molecular elements associated with an antiviral response in mucosa and blood. Clinical Immunology Communications, 2022;2:39-45.
– González S, Amador Y, Boris LG, Mojena L, Soler LL, Pish G, et al. Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin. J Oncol. 2022 Sep 1;2022:4128946.
En la sección: COVID-19, Infectología, Inmunidad innata, Inmunidad tumoral, Inmunoterapia. Publicado en: .
– Is SARS-CoV-2 an oncogenic virus? J Infect. 2022; doi: 10.1016/j.jinf.2022.08.005 0
– Guillain-Barre syndrome: An autoimmune disorder post-COVID-19 vaccination? Clinical Immunology Communications, December 2022;2:1-5.
– Circulating multimeric immune complexes contribute to immunopathology in COVID-19. Nature Communications, 2022;13:5654.
– SARS-CoV-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophages. Science Translational Medicine, 2022; DOI: 10.1126/scitranslmed.abm9151
– Covid-19 Vaccines — Immunity, Variants, Boosters. N Eng J Med, 2022; DOI: 10.1056/NEJMra2206573
– HLA alleles, disease severity, and age associate with T-cell responses following infection with SARS-CoV-2. Communications Biology, 2022;5:914.
– Sensing of SARS-CoV-2 by pDCs and their subsequent production of IFN-I contribute to macrophage-induced cytokine storm during COVID-19. Science Immunology, 2022;7(75).
En la sección: Autoinmunidad, COVID-19, Infectología, Inmunidad innata, Inmunidad tumoral. Publicado en: .
– Carmenate T, Montalvo G, Lozada SL, Rodriguez Y, Ortiz Y, Díaz C, et al. The antitumor effect induced by an IL-2 ‘no-alpha’ mutein depends on changes in the CD8 + T lymphocyte/Treg cell balance. Front Immunol. 2022 Aug 17;13:974188.
– Evans R, Lee K, Wallace PK, Reid M, Muhitch J, Dozier A, et al. Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC. Front Oncol. 2022 Aug 3;12:958043.
En la sección: Autores cubanos en revistas extranjeras, Inmunidad tumoral, Inmunoterapia, Linfocitos T. Publicado en: .
– A new chapter for anti-idiotypes in low molecular weight compound immunoassays. Trends in Biotechnology, 2022;40(9):1102-1120.
– Chronic Urticaria. N Engl J Med 2022;387:824-831.
– Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations. BMJ 2022;378:e068956.
– Refractory immune thrombocytopenia: lessons from immune dysregulation disorders. Front. Med., 2022; doi: 10.3389/fmed.2022.986260.
– Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review of PubMed/MEDLINE case reports from 1980 to 2020. Front. Med., 2022; https://doi.org/10.3389/fmed.2022.949520
– The roles of extracellular vesicles in the immune system. Nature Reviews Immunology, 2022; https://doi.org/10.1038/s41577-022-00763-8
– The evolving role of tissue-resident memory T cells in infections and cancer. Science Advances, 2022;8(33).
En la sección: Artículos de revisión, Autoinmunidad, Hipersensibilidad, Inmunidad tumoral, Inmunoterapia, Linfocitos T, Tecnologías. Publicado en: .
La secuencia de eventos: complejo de ataque a la membrana, activación de neutrófilos, liberación de NETs y daño a la pared endotelial, permitirían la entrada de células de melanoma a la circulación sanguínea y su diseminación. Así se propone en Liu X, Wang Y, Bauer AT, Kirschfink M, Ding P, Gebhardt C, et al. Neutrophils activated by membrane attack complexes increase the permeability of melanoma blood vessels. PNAS, 2022;119(33):e2122716119.
En la sección: Inmunidad innata, Inmunidad tumoral. Publicado en: .